Augmented Sensory in Cancer-Related Neuropathic Patients"

Design: A randomized control trial was conducted to investigate the impact of augmented sensory feedback paradigm on motor control and risk of falling in patient with Chemotherapy-induced peripheral neuropathy. Data were collected pre and post treatment from out-patient clinic of the Faculty of Medicine and Faculty of Physical Therapy South Valley University, between January 2023and March 2024. The study was approved by the ethical committee of the Faculty of Physical Therapy, South Vally University, Egypt. The study protocol was explained in detail to every patient and signed written consent was obtained before participation.

Participants: forty female patients with CIPN were recruited from out-patient clinic of the Faculty of Medicine and Faculty of Physical Therapy South Valley University, between January 2023and March 2024.

Inclusion criteria

• Forty female with age from 35-60 years
• clinically diagnosed with CIPN after recovery from stage I or II breast cancer
• The strength at the toes, ankles, knees, and hips, as determined by manual muscle tests, of at least 3/5.
• The patients can walk independently with or without any assistive devices.

Exclusion criteria

• Patients with a history of hereditary peripheral neuropathy
• Diseases that may contribute to peripheral nerve damage, such as diabetes or renal insufficiency, alcohol abuse, HIV, and vasculitis.
• Patient who had central or peripheral neurologic disease, brain or spinal cord metastases
• Orthopedic problems influencing gait, or foot ulcer at the moment of intake.
• Patients with vestibular or neurological problems influencing gait parameters
• Subjects who had participated in regular exercise, as defined as 150 min of light-to-moderate intensity exercise per week over the past year, were excluded from this trial.